Skip to content
Friday 28 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE · FR
MorningWire

European business, markets and politics

FTSE 100
10,824.26
+0.29%
DAX
26,569.99
+0.77%
CAC 40
8,401.18
+0.98%
STOXX 50
6,485.67
+0.95%
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
More
GermanyFranceEU InstitutionsCompetitionPublic AffairsBankingTechnologyEnergy
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Regulation
  • Politics
  • Opinion
  • DE
Wednesday 20 December 2023 4:50 pm  |  Updated:  Wednesday 20 December 2023 4:03 pm

Sniffer dogs root out drug use at Tory donor JCB’s UK factory: report

By: Guy Taylor

Transport Reporter

Add as a preferred source on Google
Manufacturing giant JCB is investigating a string of drug use incidence among its workers based at its Staffordshire headquarters.
Manufacturing giant JCB is investigating a string of drug use incidence among its workers based at its Staffordshire headquarters.

Manufacturing giant JCB is investigating a string of drug use incidents among its workers based at its Staffordshire headquarters and has sacked a number of staff, according to reports.

A message from JCB’s human resources director to UK employees, seen by the Guardian, said the company had conducted a “series of investigations into substance misuse” over the past two months, which resulted in a “small but significant number of people leaving JCB.”

Sniffer dogs deployed at its site over a week-long period rooted out 22 staff who subsequently tested positive for either drugs or alcohol, or refused to take a drugs test, the company, through its lawyers Schillings, revealed.

Some 75 per cent of those tested positive for cannabis through urine tests, it added, while further laboratory tests were being carried out on the results.

The digger-maker told the Guardian the staff did not hold senior management positions, but would not confirm whether any class A drugs such as cocaine were found in the tests. A further 11 UK workers have either been sacked or resigned between April and December for refusing to take part in drug and alcohol tests or recording a positive test, it added.

A spokesman for JCB told City A.M: “The health and safety of everyone working at JCB is the company’s top priority. The risks posed by substance misuse and alcohol abuse in the workplace can be very serious, and for this reason, JCB has a zero-tolerance approach to the issue.”

JCB is controlled by the major conservative party donors, the Bamford family, and is one of the UK’s largest manufacturers. Some 8,000 staff work in its UK offices, with its global employee count numbering around 15,000.

The Bamford family has given tens of thousands to the former prime minister Boris Johnson, including to fund his wedding celebrations last summer. The company’s chair, the billionaire Anthony Bamford, is seperately under investigation by HMRC over his tax affairs.

After questions from the Guardian, JCB’s lawyers said on Tuesday that it investigated allegations managers had been supplied with drugs in October. The company was shown alleged screenshots of messages dating to July 2023, which appeared to show three employees buying and using drugs, the newspaper reported.

JCB’s lawyers’ Schillings were approached for comment.

Read more

Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Morning Wire Content
  • Transport & Infrastructure

Trending Articles

  • Pensioners to hand over bank statements in government benefits crackdown

  • Jamie Carragher: HMRC petitions for Sky Sports star to be declared bankrupt

  • Brewdog founder James Watt hits out at ‘total silence’ over new venture

  • Lloyds Bank and Halifax users unable to use app in latest outage

  • Economists urge Bank of England to halt bond sales as borrowing costs climb

More from Morning Wire

  • Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

    Business Wire
  • Astrazeneca share price tumbles on $400bn megamerger talks

    Investing
    Astrazeneca headquarters with logo, reflecting commitment to reduce US medicine prices after Trump administration pressure
  • Compass Pathways Announces Second Quarter and First Half 2026 Financial Results and Business Highlights

    Business Wire
  • Whey and weight-loss drugs to eat into Applied Nutrition profit

    Retail
    Woman lifting dumbbells with a trainer in a busy gym, promoting fitness and health
  • Astrazeneca explores $400bn megadeal with US rival 

    Markets
    AstraZeneca building exterior with logo, glass facade, UK flag, and wildflowers in foreground.
  • ReNew Reports 25.6% Reduction in Scope 1 & 2 Emissions and 24.7 Billion Units of Clean Power Generated in FY 2025-26

    Business Wire
  • The real scrutiny of Burnham begins now

    Opinion
    Andy Burnham smiling and playing guitar in Ukraine next to a soldier in uniform adjusting audio equipment
  • John Lewis boss quits after warnings of ‘really tough’ trading

    Retail
    Two men, one in an olive green coat, the other in a blue blazer, both smiling.
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • EU Institutions
  • Europe

Business

  • Markets
  • Business
  • Economy
  • Regulation
  • Competition
  • Public Affairs

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook